Nexafed has also demonstrated the ability to block the extraction of the pseudoephedrine from the tablets, which is the first step in the two other common methods of producing the illicit drug methamphetamine.
Nexafed is a 30mg pseudoephedrine hydrochloride tablet formulation utilizing Acura’s IMPEDE Technology and intended to be used as a treatment for nasal congestion associated with colds and allergies.
Acura expects to launch Nexafed to pharmacies later in 2012.
Acura technical affairs vice president Albert Brzeczko said that IMPEDE technology has demonstrated an impact on the three common methods of illicit methamphetamine production.
"We believe processing Nexafed in an actual pseudoephedrine-to-methamphetamine conversion process is the most definitive test we could perform," Brzeczko added.